Anil Dangi1,2, Shuangjin Yu2, Xunrong Luo1,2,3. 1. Center for Kidney Research and Therapeutics, Feinberg Cardiovascular Research Institute. 2. Division of Nephrology and Hypertension, Department of Medicine. 3. Comprehensive Transplant Center, Northwestern University Feinberg School of Medicine, Chicago, Ilinois, USA.
Abstract
PURPOSE OF REVIEW: This article is aimed to provide readers with an updated review on the applicability, efficacy, and challenges of employing donor apoptotic cell-based therapies to promote transplantation tolerance in various experimental and clinical settings. RECENT FINDINGS: Recently, donor apoptotic cell-based therapies have been employed in various models of cell (including pancreatic islets and bone marrow hematopoietic stem cells) and solid organ (heart and kidney) transplantation to promote donor-specific tolerance. Published data, thus far, have revealed a high potential of this approach in inducing robust transplantation tolerance. Recent clinical trials have also underscored the safety and potential efficacy of this approach in alleviating graft-versus-host disease (GVHD) in bone marrow transplantation (BMT). Host factors including prior allo-sensitization and opportunistic infections pose major obstacles in establishing transplantation tolerance employing this strategy. However, emerging data provide strategies for overcoming such obstacles in these clinically relevant settings. SUMMARY: Donor apoptotic cell therapy is an emerging strategy in promoting transplantation tolerance, with recent data emphasizing its efficacy and applicability for transplantation tolerance in the clinic.
PURPOSE OF REVIEW: This article is aimed to provide readers with an updated review on the applicability, efficacy, and challenges of employing donor apoptotic cell-based therapies to promote transplantation tolerance in various experimental and clinical settings. RECENT FINDINGS: Recently, donor apoptotic cell-based therapies have been employed in various models of cell (including pancreatic islets and bone marrow hematopoietic stem cells) and solid organ (heart and kidney) transplantation to promote donor-specific tolerance. Published data, thus far, have revealed a high potential of this approach in inducing robust transplantation tolerance. Recent clinical trials have also underscored the safety and potential efficacy of this approach in alleviating graft-versus-host disease (GVHD) in bone marrow transplantation (BMT). Host factors including prior allo-sensitization and opportunistic infections pose major obstacles in establishing transplantation tolerance employing this strategy. However, emerging data provide strategies for overcoming such obstacles in these clinically relevant settings. SUMMARY:Donor apoptotic cell therapy is an emerging strategy in promoting transplantation tolerance, with recent data emphasizing its efficacy and applicability for transplantation tolerance in the clinic.
Authors: Luis E Muñoz; Kirsten Lauber; Martin Schiller; Angelo A Manfredi; Martin Herrmann Journal: Nat Rev Rheumatol Date: 2010-05 Impact factor: 20.543
Authors: E Pouliquen; P Baltzinger; A Lemle; C-C Chen; A Parissiadis; S Borot; L Frimat; S Girerd; T Berney; S Lablanche; P Y Benhamou; E Morelon; L Badet; V Dubois; L Kessler; O Thaunat Journal: Am J Transplant Date: 2016-07-25 Impact factor: 8.086
Authors: H B Zheng; B Watkins; V Tkachev; S Yu; D Tran; S Furlan; K Zeleski; K Singh; K Hamby; C Hotchkiss; J Lane; S Gumber; A B Adams; L Cendales; A D Kirk; A Kaur; B R Blazar; C P Larsen; L S Kean Journal: Am J Transplant Date: 2016-09-19 Impact factor: 8.086
Authors: Tatsuo Kawai; A Benedict Cosimi; Thomas R Spitzer; Nina Tolkoff-Rubin; Manikkam Suthanthiran; Susan L Saidman; Juanita Shaffer; Frederic I Preffer; Ruchuang Ding; Vijay Sharma; Jay A Fishman; Bimalangshu Dey; Dicken S C Ko; Martin Hertl; Nelson B Goes; Waichi Wong; Winfred W Williams; Robert B Colvin; Megan Sykes; David H Sachs Journal: N Engl J Med Date: 2008-01-24 Impact factor: 91.245
Authors: Adrian E Morelli; Adriana T Larregina; William J Shufesky; Alan F Zahorchak; Alison J Logar; Glenn D Papworth; Zhiliang Wang; Simon C Watkins; Louis D Falo; Angus W Thomson Journal: Blood Date: 2002-09-05 Impact factor: 22.113
Authors: Shusen Wang; James Tasch; Taba Kheradmand; Jodie Ulaszek; Sora Ely; Xiaomin Zhang; Bernhard J Hering; Stephen D Miller; Xunrong Luo Journal: Diabetes Date: 2013-07-12 Impact factor: 9.461
Authors: Anil Dangi; Shuangjin Yu; Frances T Lee; Melanie Burnette; Jiao-Jing Wang; Yashpal S Kanwar; Zheng J Zhang; Michael Abecassis; Edward B Thorp; Xunrong Luo Journal: Kidney Int Date: 2020-02-21 Impact factor: 10.612
Authors: Shuangjin Yu; Anil Dangi; Melanie Burnette; Michael M Abecassis; Edward B Thorp; Xunrong Luo Journal: Am J Transplant Date: 2020-08-17 Impact factor: 8.086